NARILIS PhD student Hélène Haguet wins the LEO Pharma Award "Cancer & Thrombosis"
Hélène Haguet's research focuses on the cardiovascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors (TKIs) administered to patients with chronic myeloid leukemia.
This research project of the Namur Thrombosis & Hemostasis Center (NTHC) was initiated by Dr. Jonathan Douxfils. It involves both the Department of Pharmacy of the UNamur (Prof. Jean-Michel Dogné) and the Hematology Laboratory of the CHU UCL Namur (Prof. François Mullier).
A systematic review and meta-analysis of randomized controlled trials performed by Jonathan Douxfils and Hélène Haguet demonstrated that 3 new generation TKIs (dasatinib, nilotinib and ponatinib) are associated with an increased risk of cardiovascular events, compared to imatinib, the first approved TKI. These data were reported for the first time early 2016 in "JAMA Oncology" (see publication 2016). More recently, an updated meta-analysis was published in the journal "Expert Opinion on Drug Safety" (see publication 2017).
During the 19th annual meeting of the Belgian Society of Medical Oncology (BSMO) held on 24-25 February 2017, Hélène Haguet has been awarded the LEO Pharma Prize "Cancer & Thrombosis", which aims at recognizing a publication in the field of thromboembolic diseases linked to cancer.
Congratulations to Hélène and all the NTHC team!